Citadel Advisors
TARS icon

Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
+15,900
New +$1.11M ﹤0.01% 7428
2025
Q4 		– Sell
-6,600
Closed -$392K – 14044
2025
Q3 		$392K Sell
6,600
-1,200
-15% -$59.1K ﹤0.01% 9712
2025
Q2 		$316K Sell
7,800
-6,800
-47% -$306K ﹤0.01% 9695
2025
Q1 		$750K Buy
14,600
+2,200
+18% +$109K ﹤0.01% 7594
2024
Q4 		$687K Sell
12,400
-2,400
-16% -$109K ﹤0.01% 7873
2024
Q3 		$487K Buy
14,800
+7,900
+114% +$222K ﹤0.01% 8313
2024
Q2 		$188K Sell
6,900
-5,200
-43% -$175K ﹤0.01% 10035
2024
Q1 		$440K Sell
12,100
-600
-5% -$17.6K ﹤0.01% 8672
2023
Q4 		$257K Buy
12,700
+800
+7% +$13.4K ﹤0.01% 9470
2023
Q3 		$211K Buy
11,900
+9,200
+341% +$163K ﹤0.01% 9794
2023
Q2 		$48.8K Buy
2,700
+2,200
+440% +$35K ﹤0.01% 11830
2023
Q1 		$6.29K Sell
500
-38,900
-99% -$569K ﹤0.01% 13819
2022
Q4 		$578K Buy
39,400
+500
+1% +$8.27K ﹤0.01% 7942
2022
Q3 		$666K Buy
38,900
+1,400
+4% +$22.2K ﹤0.01% 7852
2022
Q2 		$548K Buy
+37,500
New +$563K ﹤0.01% 8442

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's TARS Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2026: 163,997 shares worth $11.5M. The stake represents ﹤0.01% of the portfolio and ranks #3062 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TARS as recently as Q3 2025.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 15 quarters since. The position peaked at $51M in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Citadel Advisors held 163,997 shares of Tarsus Pharmaceuticals worth $11.5M as of Q1 2026.
  • Tarsus Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3062 holding.
  • Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.